Antibe is a commercial stage pharmaceutical company focused on pain, inflammation and regenerative medicine. Antibe s lead drug, ATB , targets the global need for a safer non steroidal anti inflammatory drug NSAID for treating chronic pain and inflammation with non addictive medication. Antibe s subsidiary, Citagenix Inc. Citagenix , is a leader in Canada in the sales and marketing of tissue regenerative products servicing the dental and orthopaedic marketplaces. Since its inception in , Citagenix has become an important source of knowledge and experience in the Canadian medical device industry. Citagenix has grown a comprehensive portfolio of high quality, branded biologics and medical devices that promote bone regeneration. Citagenix is active in countries, operating in Canada through its direct sales teams, and internationally via a network of distributor partnerships.
Quote | Antibe Therapeutics (OTCMKTS:ATBPF)
Last: | $0.2156 |
---|---|
Change Percent: | 12.38% |
Open: | $0.1889 |
Close: | $0.2156 |
High: | $0.2452 |
Low: | $0.1889 |
Volume: | 33,935 |
Last Trade Date Time: | 04/08/2024 03:00:00 am |
News | Antibe Therapeutics (OTCMKTS:ATBPF)
Antibe Therapeutics Inc. (“ Antibe ” or the “ Company ”) (TSX: ATE, OTCQX: ATBPF) announced that its previously announced application for an Initial Order under the Companies' Creditors Arrangement Act (the " CCAA "), has been granted by the Ontario Sup...
Antibe Therapeutics Inc. (“ Antibe ” or the “ Company ”) (TSX: ATE, OTCQX: ATBPF) announced that it intends to file an application today with the Ontario Superior Court of Justice (Commercial List) (the " Court ") for an Initial Order under the Companies'...
Message Board Posts | Antibe Therapeutics (OTCMKTS:ATBPF)
Subject | By | Source | When |
---|---|---|---|
This board is a ghost town. | kahlua | investorshub | 12/04/2022 9:53:23 AM |
https://m.canadianinsider.com/node/7?ticker=ATE&fbclid=IwAR3q4E-W8ZRcSlyhCwwamd | treedoc | investorshub | 08/06/2021 11:22:25 AM |
https://www.biospace.com/article/releases/antibe-therapeutics-provides-clinical | treedoc | investorshub | 08/03/2021 12:14:16 PM |
Received proxy material | treedoc | investorshub | 07/17/2021 1:26:31 PM |
https://www.lelezard.com/en/news-19876628.html | treedoc | investorshub | 06/28/2021 11:38:27 AM |
News, Short Squeeze, Breakout and More Instantly...
Antibe Therapeutics Inc. (“ Antibe ” or the “ Company ”) (TSX: ATE, OTCQX: ATBPF) announced that its previously announced application for an Initial Order under the Companies' Creditors Arrangement Act (the " CCAA "), has been granted by the Ontario Sup...
Antibe Therapeutics Inc. (“ Antibe ” or the “ Company ”) (TSX: ATE, OTCQX: ATBPF) announced that it intends to file an application today with the Ontario Superior Court of Justice (Commercial List) (the " Court ") for an Initial Order under the Companies'...
Antibe Therapeutics Inc. (“Antibe” or the “Company” TSX: ATE, OTCQX: ATBPF) today announced that it received verbal notice on the afternoon of March 28, 2024 from the U.S. Food and Drug Administration (“FDA”) that otenaproxesul has been placed on clinical...